Educational deep-dive on a forensic earnings-quality metric — illustrated, not recommended. This is not a buy/sell recommendation on any stock, including Titan Biotech Limited (BSE: 524717).
Why This One Line in the P&L Decides Whether You Are Reading a Real Operating Business or a Non-Operating Bookkeeper
The Securities and Exchange Board of India’s January 2024 study on individual traders in the equity Futures & Options segment is now the single most-cited statistic in Indian retail investing: 9 out of 10 — 93% — of individual F&O traders incurred net losses, with aggregate losses crossing ₹1.81 lakh crore over a three-year window. Meanwhile, NSE’s investor base has expanded from roughly 3 crore unique investors in 2019 to more than 11 crore by early 2026. The numerical contrast tells the story: tens of millions of new equity participants have rushed into India’s markets, and the overwhelming majority of those who try to “trade their way to wealth” lose money. The structural answer the regulators keep pointing to is the same answer Benjamin Graham gave in 1934 — read the financial statements, do the work, and learn to separate real businesses from accounting shells.
Among all the line items on a profit & loss statement, one is uniquely capable of revealing whether a company is genuinely an operating business or merely a non-operating bookkeeper dressed up to look like one: Other Income. And the single most important way to read it is as a percentage of profit before tax: Other Income as a percentage of PBT. If a company’s profits are dominated by other income — interest on cash piles, dividends from cross-holdings, mark-to-market gains, sale of fixed assets, foreign-exchange windfalls — the headline net profit is real but the underlying business may not be. Conversely, if Other Income is a small, predictable, supplementary line and the bulk of PBT is generated by the core operating activity, the company is what it appears to be: a business.
This article teaches you exactly how to read this metric, what thresholds Indian long-term investors should apply, where the traps lie, and finally — using Titan Biotech Limited’s FY25 audited financials as a positive illustration — how a disciplined, operating-cash-flow-led earnings profile actually looks on the page.
What Is “Other Income” in an Indian P&L?
Under Schedule III of the Companies Act, 2013 — the format every listed Indian company must use — the consolidated Profit & Loss statement separates revenue into two distinct top-line items:
Revenue from Operations: sale of products, sale of services, and any other operating revenue earned from the company’s principal business activity.
Other Income: non-operating income that does not arise from the principal business activity. Indian Accounting Standard (Ind AS) 1 and Schedule III require this to be disclosed separately, with an additional sub-schedule (typically “Note: Other Income”) breaking down its components.
Common items inside the Other Income note for Indian listed companies include: interest income on bank deposits, interest on investments and bonds, dividend income from equity investments, net gain on sale of investments, net gain on sale of fixed assets, foreign-exchange gain (net), liabilities/provisions written back, government grants amortised, insurance claims received, rental income from sub-letting unused property, miscellaneous income.
None of these are bad in isolation. A company that conservatively parks surplus cash and earns interest is doing exactly what shareholders want it to do with idle balances. The forensic question is not whether Other Income exists — it almost always does — but how large it has become relative to the profit the company actually reports to shareholders and to the tax authorities.
The Formula and How to Read It
The metric is calculated as:
Other Income as % of PBT = (Other Income ÷ Profit Before Tax) × 100
Both numerator and denominator are taken straight from the consolidated P&L statement. PBT is preferred to net profit because tax rates can fluctuate (Section 115BAA elections, deferred tax movements, MAT credits) and you want a metric that is unaffected by tax accounting noise. Some forensic analysts prefer the variant Other Income as % of EBIT or Other Income as % of Operating Profit — those are equally valid and tighter, but PBT is the most readily available number from any disclosure source (BSE filing, annual report, screener.in) and gives a directionally identical answer.
How to read the resulting percentage in the Indian context, calibrated to FY15–FY25 data on the BSE 500 universe:
Below 5%: The company’s profits are almost entirely operating in nature. Other Income is supplementary — typically just interest on the operating cash pile. This is the cleanest possible reading and is the norm for high-quality manufacturing, FMCG, IT services, and pharma franchises with disciplined capital allocation.
5%–15%: Healthy and normal for most Indian operating businesses. The company is generating modest non-operating income from prudently parked surplus cash. Worth checking the breakdown but rarely a red flag.
15%–30%: Worth investigating. The company is either holding very large cash piles relative to its operating profitability (which raises capital allocation questions), or has begun to rely on one-off items (asset sales, FX gains, write-backs) to support headline PBT. Read the Other Income note line by line.
30%–50%: Yellow flag. A meaningful share of headline profit is non-operating. The core business is either weak, capital-intensive but under-earning, or the company is essentially an investment holding entity wearing the costume of an operating company.
Above 50%: Red flag for any retail investor expecting to value the entity as an operating business. The numbers are telling you the operating business is not the source of profit — the balance sheet is. Holding companies and pure investment vehicles legitimately sit here, but they should be valued using a sum-of-the-parts framework with a holding-company discount, not a P/E multiple on consolidated PAT.
Why This Metric Matters More for Indian Investors Than Most Realise
India’s accounting and disclosure framework has tightened considerably in the past decade — Ind AS adoption, IndAS 115 on revenue recognition, Schedule III amendments, KRA-mandated forensic auditing for SEBI-registered intermediaries — but the line between “operating” and “non-operating” income remains one of the easiest places for management to dress up a weak quarter. A handful of Indian patterns to be aware of:
The treasury-income inflation trap: A capital-light business that has compounded earnings for a decade often ends up sitting on a cash pile that, if invested in government securities yielding 7–8%, can generate interest income equal to 20–40% of operating profit. The headline ROE looks high; the operating ROCE on the actual business may be deteriorating. Indian IT services majors, several FMCG laggards, and old-economy holding companies have shown this pattern at various points.
The asset-sale-as-profit pattern: Older Indian manufacturing companies sit on appreciating land and buildings purchased decades ago at minimal book value. Selling one parcel can flatter PBT for a single year. Investors who anchor on that “PE on TTM PAT” miss that the next year’s PBT will be 30% lower with no business deterioration whatsoever.
The FX-windfall pattern: Exporters with unhedged receivables can show 8–12% of PBT in net FX gain in any year the rupee weakens sharply. The reverse year produces an FX loss equal to the previous year’s gain. Smoothing this out by averaging over five years is the only honest way to read it.
The dividend-from-subsidiary pattern: In standalone financials of Indian holding companies, dividend received from a subsidiary often appears as Other Income. The standalone P&L therefore looks profitable while the underlying business may be a shell. The fix is to always read consolidated, not standalone, financials and to map back to operating segments.
A Tale of Two P&Ls (Generic Illustration)
Consider two anonymised mid-cap Indian companies, both showing ₹100 crore of PBT in FY25:
Company A (Disciplined Operating Profile): Revenue from Operations ₹600 crore; EBITDA ₹120 crore; Operating Profit (EBIT) ₹100 crore; Other Income ₹4 crore (interest on operating cash); Finance Cost ₹4 crore; PBT ₹100 crore. Other Income as % of PBT = 4%. The company is what it appears to be: an operating business generating real profit from sale of goods and services. The 4% Other Income is incidental treasury yield on working-capital cash.
Company B (Bookkeeper Profile): Revenue from Operations ₹900 crore; EBITDA ₹70 crore; Operating Profit (EBIT) ₹30 crore; Other Income ₹85 crore (₹40 crore interest on a ₹500 crore cash pile, ₹25 crore profit on sale of a Mumbai land parcel, ₹20 crore mark-to-market gain on quoted equity investments); Finance Cost ₹15 crore; PBT ₹100 crore. Other Income as % of PBT = 85%. The headline PAT looks identical to Company A’s — but 85% of the profit is non-operating. The operating business is barely covering its finance cost. A retail investor anchoring on “PE of 15x” is paying for Company A but getting Company B.
This contrast is the entire point of the metric. Two companies with identical headline profits can have radically different earning power. The one-line ratio strips the disguise off in 30 seconds.
Titan Biotech FY25: What the Numbers Reveal
Titan Biotech Limited (BSE: 524717), the Bhiwadi-Rajasthan headquartered specialty biotechnology company that manufactures peptones, microbial culture media, collagen and gelatin for pharma and biotech customers across more than 60 countries, presents an exceptionally clean operating-earnings profile in its FY25 audited financials. The numbers below are drawn from Titan Biotech’s audited FY25 disclosures and are used here strictly as a positive educational illustration of what disciplined operating-led earnings look like in a real Indian listed company. No part of this section constitutes a buy/sell recommendation.
| FY25 Audited Marker (Titan Biotech) | Reported Value | What It Tells the Reader |
|---|---|---|
| Total Revenue FY25 (4-quarter sum) | ~₹214 Cr | The top line is operating revenue from the core biotech franchise — sales of peptones, media, collagen, gelatin to pharma customers globally. |
| QoQ Revenue Arc FY25 | ₹46.5 Cr → ₹54 Cr → ₹56 Cr → ~₹58 Cr | Sequential growth in operating revenue every quarter — the engine of profit is the operating business, not non-operating sources. |
| Total Borrowings FY25 | ₹3 Cr (essentially debt-free) | Negligible interest-bearing debt → finance cost on the P&L is structurally tiny → almost nothing offsets non-operating income before PBT. |
| EBITDA Margin FY25 | ~18–22% range | Operating profitability is robust. EBITDA is the dominant component of PBT before any treasury or non-operating line is added. |
| CFO / Operating Profit FY25 | ~103% | Cash generated from operations slightly exceeds operating profit → operating earnings are not just real, they are over-collected in cash. Other Income contribution is incidental. |
| 10-year Revenue CAGR | ~15% | Top-line compounded for a decade through operations, not asset disposals or treasury bets. |
| 10-year PAT CAGR | ~29% | PAT compounded almost 2x the revenue rate through operating leverage — non-operating income is too small a base to drive this. |
| Gross Block FY25 | ~₹57 Cr | Asset base is genuinely productive — a manufacturing operation, not a holding-company shell. |
| Capital Work-In-Progress FY25 | ~₹11 Cr | Money is being committed to the next leg of operating capacity expansion, not to financial investments. |
| Independent Chairperson + 14 Board Meetings FY25 | Best-practice governance | The board structure that signs off on the disclosures is independently chaired and meets 3.5x the SEBI minimum — adding credibility to the Other Income classification itself. |
Reading the markers as a system: Titan Biotech’s FY25 P&L is structurally an operating-earnings P&L. The combination of (a) ~18–22% EBITDA margin on ₹214 crore of operating revenue, (b) a CFO/OP ratio of ~103% (cash collection actually exceeds book operating profit), and (c) borrowings of just ₹3 crore means the operating business does the heavy lifting on every single rupee of PBT. There is no large treasury portfolio whose interest could dominate Other Income, no debt-fuelled balance sheet whose finance cost masks non-operating gains, and no pattern of asset disposals propping up a quarter. When an Indian biotech company shows you both 15% revenue CAGR and 29% PAT CAGR over a decade with this kind of clean operating disclosure, the long-term investor is being given a textbook example of operating-led earnings quality. That is the educational point — not a verdict on the share price.
Why this matters for how you read the rest of the report: Once you have established that operating earnings dominate, every other line on the financials becomes easier to interpret. Working capital changes are real (not paper). Tax expense is on operating profit (not on accounting gains that may not recur). Dividend capacity is funded from cash earned, not cash raised. And critically, the fair-value question becomes a question about a real operating business — not about a portfolio of investments wearing a manufacturing costume.
How a Long-Term Indian Retail Investor Should Use This Metric
The Other Income / PBT ratio is not a ratio you compute once. It is a ratio you compute over five to ten years and look at as a series. Here is the practical workflow:
Step 1 — Pull a 10-year series. From screener.in, BSE filings, or the company’s annual reports, extract Other Income and PBT for each of the last ten financial years. Compute the ratio for each year. A single year tells you nothing; the trend tells you everything.
Step 2 — Look for the median, not the average. Asset-sale-driven outliers can pull the average upward. The median across ten years is the steadier reading. A median below 10% with low variability is the cleanest possible operating-earnings profile.
Step 3 — Read the Other Income note. If the metric is rising, open the “Other Income” sub-note in the latest annual report and identify which line is growing. Interest income rising in line with cash balance is benign. Profit on sale of investments or fixed assets rising is a yellow flag.
Step 4 — Cross-check against CFO. If Other Income is dominated by non-cash items (mark-to-market gains, write-backs, deferred grant amortisation), CFO will not move with PBT. The cash-flow statement is the truth-test for whether other income is “real money” or “accounting profit”. This is exactly why the SEBI-mandated cash-flow disclosure exists.
Step 5 — Adjust the multiple. If 30%+ of a company’s PBT is non-operating, you cannot value it on a simple PE on consolidated PAT. Either adjust PAT downward (strip out the non-recurring portion) or value the company on a sum-of-the-parts basis. Pretending non-operating income will compound at the same rate as operating earnings is the single biggest valuation error retail investors make on Indian small-caps.
Common Traps and Misinterpretations
Trap 1: Confusing Other Income with Other Comprehensive Income (OCI). These are entirely different sections of an Ind AS P&L. Other Income sits above the line and contributes to PBT. OCI sits below the line, includes items like remeasurement of defined benefit plans and FX translation differences on foreign operations, and does not flow through PAT. Many beginners mix these up and assume a company has a huge non-operating profit when it actually has a routine OCI movement.
Trap 2: Reading standalone instead of consolidated. For Indian holding companies, standalone Other Income often includes dividends from subsidiaries — making the parent look like a non-operating bookkeeper. Always use consolidated financials. The dividend from the subsidiary eliminates on consolidation and the underlying operating profit of the subsidiary appears on the consolidated P&L instead.
Trap 3: Ignoring the size effect. A small-cap with ₹50 crore PBT and a sudden ₹20 crore profit on sale of a small office property shows 40% Other Income / PBT — but the next year that drops to 4%. A large-cap rarely has a single asset of comparable proportion. Always size the ratio against the company’s market cap and asset base.
Trap 4: Treating treasury income as bad in itself. A company with a strong cash-generative business that compounds cash on its balance sheet and earns 7–8% on government securities is doing exactly what disciplined capital allocation looks like in the absence of high-RoIC reinvestment opportunities. The question is whether the operating business is also doing well — not whether Other Income exists.
Trap 5: Anchoring on the latest single year. Other Income is one of the most volatile lines on any Indian P&L because of asset sales, FX, and one-off government grants. A single year is noise. A ten-year series is signal.
Putting It All Together: The 30-Second Forensic Test
When you next open the annual report of any Indian listed company, before you look at PE, before you look at growth, before you look at any moat narrative — do the following 30-second sequence:
One. Open the consolidated P&L. Find Revenue from Operations and Other Income. Find PBT.
Two. Compute Other Income / PBT. If it is below 10%, the operating business is doing the work. If it is between 10% and 30%, read the Other Income note. If it is above 30%, treat the company as a hybrid operating-investment vehicle and value it accordingly.
Three. Pull last five years’ Other Income / PBT. If the ratio is rising, the operating business is decelerating relative to non-operating sources. If the ratio is stable or falling, the operating business is leading.
Four. Cross-check with CFO. If CFO is rising in step with PAT, the earnings are real. If PAT is rising while CFO is flat, the non-operating income is largely paper.
That is the entire test. Two ratios, one cross-check, four numbers. It will not tell you whether to buy a stock. It will tell you whether the company you are looking at is the kind of company that compounds wealth for shareholders by doing real economic work — or merely by holding assets that some prior generation accumulated.
For Indian long-term investors who have watched their friends lose ₹1.81 lakh crore in F&O over three years while building no underlying knowledge of the businesses behind the tickers, this is the kind of slow, boring, patient work that compounds into actual edge. The 93% who lose money in derivatives are not unintelligent — they are simply unwilling to read the four lines we just walked through. The 7% who do not lose, in the long run, are very often the ones who do this work.
Key Takeaways
- Other Income as a % of PBT is the 30-second forensic filter that separates real Indian operating businesses from non-operating bookkeepers. Below 10% on a 10-year median is the cleanest possible reading; above 30% requires reading the company as a hybrid operating-investment entity.
- The metric must be read as a 5–10-year series, not a single year. Asset sales, FX swings, and one-off government grants distort any single year. The median and trend, read against the Other Income sub-note in the annual report, are what matter.
- Titan Biotech FY25’s audited disclosure shows what an operating-led earnings profile looks like in practice: ~₹214 Cr operating revenue, ~18–22% EBITDA margin, CFO/Operating Profit at ~103%, total borrowings just ₹3 Cr, ~10-year revenue CAGR of 15% and PAT CAGR of ~29% — a textbook profile of a real operating business compounding through its core franchise. This is an educational illustration of disciplined fundamentals, not a buy/sell recommendation.
- Always cross-check against CFO and always read consolidated, not standalone, financials. A rising Other Income / PBT ratio that is not matched by rising CFO is a signal that the headline profit is becoming increasingly paper-driven — exactly the kind of slow-developing red flag that the cash-flow statement was designed to catch.
SEBI Disclaimer
Disclaimer: This article is for educational and informational purposes only. It is not investment advice, and not a buy, sell, or hold recommendation on any stock mentioned, including Titan Biotech Limited. Equity markets carry risk; please do your own research or consult a qualified professional before making investment decisions.
